The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Long-term outcome of patients with R/R LBCL achieving CR using bispecific antibodies
Evgenii Shumilov, MD, University Hospital Münster, Münster, Germany, comments on the long-term outcome of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) achieving complete remission (CR) using bispecific antibodies. Dr Shumilov reports that, although with a shorter follow-up, the data confirm the encouraging results seen in pivotal studies, with patients sustaining CR. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we know that patients with complete remission, I mean patients with relapsed refractory large B-cell lymphoma who achieve complete remission on specific antibodies perform very well according to pivotal studies and in the clinical practice we see this tremendous clinical course when patients are refractory then receive bispecific antibodies and it’s like a miracle they achieve CR and then nothing happens so they stay in remission and accordingly alive...
So we know that patients with complete remission, I mean patients with relapsed refractory large B-cell lymphoma who achieve complete remission on specific antibodies perform very well according to pivotal studies and in the clinical practice we see this tremendous clinical course when patients are refractory then receive bispecific antibodies and it’s like a miracle they achieve CR and then nothing happens so they stay in remission and accordingly alive. So following that we aim to investigate in the real-world practice how CR patients perform. For that we collected 53 patients from 33 centers from Germany, Austria, Italy and Switzerland, Swiss. And indeed we could confirm although we had a shorter follow-up we could confirm very encouraging data of pivotal approval studies that see our patients have a sustained complete remission and stay alive for a long time. So it suggests that we cure a significant part of these patients, particularly those who have end of treatment with glofitamab or at least 12 cycles of epocoritamab. They perform very well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
